Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 2
2019 2
2020 2
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
Pott C, Jurinovic V, Trotman J, Kehden B, Unterhalt M, Herold M, Jagt RV, Janssens A, Kneba M, Mayer J, Young M, Schmidt C, Knapp A, Nielsen T, Brown H, Spielewoy N, Harbron C, Bottos A, Mundt K, Marcus R, Hiddemann W, Hoster E. Pott C, et al. Among authors: kehden b. J Clin Oncol. 2024 Feb 10;42(5):550-561. doi: 10.1200/JCO.23.00838. Epub 2023 Dec 14. J Clin Oncol. 2024. PMID: 38096461 Clinical Trial.
Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.
Chitadze G, Stengel A, John-Klaua C, Bruckmüller J, Trautmann H, Kotrova M, Darzentas F, Kelm M, Pal K, Darzentas N, Bastian L, Kehden B, Wessels W, Ströh AS, Oberg HH, Altrock PM, Baer C, Meggendorfer M, Gökbuget N, Baldus CD, Haferlach C, Brüggemann M. Chitadze G, et al. Among authors: kehden b. Blood. 2023 Mar 30;141(13):1640-1644. doi: 10.1182/blood.2022017249. Blood. 2023. PMID: 36450137 Free PMC article. No abstract available.
Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.
Burmeister T, Ströh AS, Kehden B, Trautmann H, Meyer C, Marschalek R, Larghero P, Schwartz S, Steffen B, Spriewald B, Heinicke T, Jäkel N, Westermann J, Nachtkamp K, Viardot A, Topp MS, Neumann M, Baldus CD, Gökbuget N, Brüggemann M. Burmeister T, et al. Among authors: kehden b. Leukemia. 2024 Mar 22. doi: 10.1038/s41375-024-02209-7. Online ahead of print. Leukemia. 2024. PMID: 38519799 No abstract available.
MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
Pott C, Sehn LH, Belada D, Gribben J, Hoster E, Kahl B, Kehden B, Nicolas-Virelizier E, Spielewoy N, Fingerle-Rowson G, Harbron C, Mundt K, Wassner-Fritsch E, Cheson BD. Pott C, et al. Among authors: kehden b. Leukemia. 2020 Feb;34(2):522-532. doi: 10.1038/s41375-019-0559-9. Epub 2019 Aug 28. Leukemia. 2020. PMID: 31462735 Free PMC article.
Body fat percentiles for German children and adolescents.
Plachta-Danielzik S, Gehrke MI, Kehden B, Kromeyer-Hauschild K, Grillenberger M, Willhöft C, Bosy-Westphal A, Müller MJ. Plachta-Danielzik S, et al. Among authors: kehden b. Obes Facts. 2012;5(1):77-90. doi: 10.1159/000336780. Epub 2012 Mar 2. Obes Facts. 2012. PMID: 22433620 Free article.